SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ind-Swift enters into an agreement with Roche Diagnostics India

16 Jan 2012 Evaluate

Ind-Swift, a Chandigarh based pharmaceutical company has entered into an agreement with Roche Diagnostics India to promote test for detecting heart attack, TROP T rapid assay, in India. Roche Diagnostics' TROP T rapid assay is a point of care test which can detect whether a patient is having a heart attack through a simple whole blood test.

Troponin - T is used to measure damage to the heart muscle and to differentiate between non-cardiac chest pains and heart attacks. The TROP T rapid assay gives a reliable qualitative result within 15 minutes.

Ind-Swift has a cardio specific field force, CARDIASWIFT which has been marketing cardio & anti-diabetic products for the last 8-10 years. Ind-Swift will promote TROP T to cardiologists / diabectologists / consulting physicians/general practitioners all over the country with its 225 strong field force.

Roche Diagnostics India is part of Roche Group, a worldwide leader in the field of Medical Diagnostics and Pharmaceuticals.

Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence.

Ind-Swift - Amalgama Share Price

15.70 0.00 (0.00%)
13-Aug-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×